On November 17, 2026, the FDA published a proposed rule that would end one of the strangest situations in the supplement aisle. NAC (N-acetyl-L-cysteine) has been sold as a supplement in the US for more than 30 years, yet the FDA has long said it does not legally qualify as one. If the proposal becomes final, NAC would become a lawful dietary supplement ingredient.

This post explains what the proposal says, how NAC ended up in a legal gray zone in the first place, what the FDA's safety review found, what changes for people who take NAC (very little, for now), and how to comment before the deadline. For what NAC does and does not do, see our NAC benefits guide.

The short version

  • It is a proposal, not a final rule. The FDA is taking public comments until January 19, 2027. Nothing about NAC's legal status changes until a final rule is published.
  • If finalized, NAC would be a lawful supplement ingredient. The rule would create a new list in federal regulations (21 CFR 190.1) of ingredients that are "not excluded" from the dietary supplement definition, with NAC as the first entry.
  • Why it was excluded: NAC was approved as a drug in 1963, decades before the earliest supplement sale the FDA knows of, in 1991. US law excludes ingredients approved as drugs before they were sold as supplements or foods.
  • The FDA's safety review was reassuring. A systematic review of 41 high-confidence studies, at 200 to 9,000 mg a day for up to three years, found a "minimal" level of concern, mainly for stomach upset and nausea.
  • Nothing changes on the shelf right now. NAC supplements remain on sale under a 2022 FDA enforcement discretion policy, which the agency plans to withdraw once a final rule is in place.
  • It is not an endorsement of NAC's benefits. As with any supplement, products could not claim to treat or prevent disease.

What the FDA proposed

The proposal, published in the Federal Register under docket FDA-2025-N-2699, would add a new section to the federal dietary supplement regulations titled "Dietary ingredients not excluded from the dietary supplement definition." It lists one ingredient, N-acetyl-L-cysteine, and reserves space to add others later.

In practical terms, the rule would do two things:

  • Declare that NAC is not excluded from the legal definition of a dietary supplement, so products containing NAC could be lawfully marketed as supplements if they otherwise follow the law.
  • Declare that adding NAC to a dietary supplement is not a prohibited act under a separate provision that bars adding approved drugs to foods. Supplements count as foods under the law, so without this second step the first one would not work.

The FDA says this is the first time it has used this rulemaking authority, which has existed since the Dietary Supplement Health and Education Act (DSHEA) of 1994. The FDA proposes that a final rule would take effect immediately when published, because it relieves a restriction rather than imposing one. The agency estimates the total cost of the rule at about $848 (present value), essentially the cost for the few companies involved to read and understand it.

Why NAC was excluded in the first place

Under the 1994 law that defines dietary supplements, an ingredient that was approved as a new drug before it was ever marketed as a supplement or food generally cannot be sold as a supplement. This "drug exclusion" or "drug preclusion" clause exists to stop companies from relabeling drugs as supplements to avoid drug review, and to protect the incentive to develop new drugs.

NAC was approved as a drug on September 14, 1963, as Mucomyst, an inhaled treatment for thick mucus. The earliest supplement marketing the FDA could find was a 1991 magazine advertisement. Because the drug approval came first, the FDA's position has been that NAC is excluded, even though NAC itself qualifies as a dietary ingredient and supplements containing it were already on sale when the 1994 law passed. The FDA is asking for any evidence that NAC was sold as a food or supplement before 1963.

The same law gives the FDA a way out. It can issue a regulation, after public comment, finding that an excluded ingredient would be lawful as a supplement. The FDA reads the law as allowing this only when two conditions are met: regulating the ingredient as a supplement would still provide adequate safeguards, and allowing it would be unlikely to hold back new drug development. The proposal argues that NAC meets both.

For background on how supplements are regulated in general, see our guide to how supplements are regulated under DSHEA.

A timeline of NAC's legal status

DateWhat happened
September 1963NAC approved as a drug (Mucomyst, inhaled)
1991Earliest known US supplement advertisement for NAC
October 25, 1994DSHEA defines dietary supplements, including the drug exclusion clause
2001 and 2010FDA states in a health claim response and a new dietary ingredient response that NAC cannot be a dietary supplement
2004Injectable NAC (Acetadote) approved as an antidote for acetaminophen overdose
2009Original Mucomyst application withdrawn at the sponsor's request, for reasons other than safety or effectiveness; generic versions remain approved
July 2020FDA warning letters to hangover-product sellers state that NAC is excluded from the supplement definition
2021Two citizen petitions ask the FDA to allow NAC in supplements
March 2022FDA keeps its position that NAC is excluded but says it is considering rulemaking
August 2022FDA issues final guidance saying it intends to exercise temporary enforcement discretion for NAC products that would otherwise be lawful supplements while it decides
November 17, 2026FDA publishes the proposed rule; comments due January 19, 2027

Dates are as described in the FDA's proposed rule, except the date DSHEA was signed into law.

What the FDA's safety review found

To support the proposal, the FDA conducted a systematic review of published studies of NAC taken by mouth, and had it externally peer reviewed. Drug approvals weigh risks against benefits, but a supplement safety assessment considers only risk, so the agency looked at adverse events across studies, most of them outside NAC's approved drug uses.

  • The review identified 41 studies rated as high confidence.
  • Doses ranged from 200 to 9,000 mg a day, and study length from 5 days to 3 years, in groups ranging from healthy people to patients with end-stage kidney disease.
  • Most studies reported no adverse events, or no difference from comparison groups. One study found a statistically significant increase in nausea.
  • The commonly reported side effects were stomach pain or discomfort, nausea, vomiting and rash.
  • The FDA rated the level of concern as "minimal," using a five-point scale developed by the National Toxicology Program, on which only "negligible" is lower.

The FDA also compared study doses with the servings on NAC supplements, which most often recommend 600, 1,000 or 1,200 mg a day, and concluded that the study doses covered them. It found a "reasonable expectation of safety" for NAC as a supplement.

That does not mean NAC is right for everyone. Our NAC guide covers the practical cautions: NAC can interact with nitroglycerin, may have a mild blood-thinning effect, and the inhaled drug form can occasionally trigger bronchospasm in some people with asthma. If you take prescription medicines, are pregnant or breastfeeding, or have a chronic condition, talk with your doctor or pharmacist before taking it.

The drug-development question

The second condition is that allowing NAC in supplements must be unlikely to hurt drug development. The agency points to 30 years of history: NAC supplements have been sold since at least 1991, yet NAC drugs kept being approved and studied.

  • Injectable acetylcysteine (Acetadote) was approved in 2004 as an antidote for acetaminophen overdose.
  • As of April 2026, the FDA counted 19 current generic drug approvals for acetylcysteine, most granted after 1991.
  • A ClinicalTrials.gov search found 832 trials studying NAC as a drug.

The FDA says it has no reason to believe that allowing NAC supplements would affect current or future NAC drug development, and it invites comments on that point.

What changes for people who take NAC

For now, almost nothing. NAC supplements are already widely sold under the FDA's 2022 enforcement discretion policy, and that policy stays in place until the FDA either finalizes this rule or denies the petition's request for rulemaking. If the rule is finalized:

  • NAC becomes an ordinary supplement ingredient. Retailers and manufacturers would no longer be relying on a temporary policy, which could make NAC easier to find and more likely to appear in new products.
  • Normal supplement rules apply. NAC products would continue to have to follow good manufacturing practices and supplement labeling rules, and the FDA could act against products that are adulterated or misbranded.
  • No disease claims. As with every supplement, NAC products could not claim to treat, cure or prevent disease. The 2020 warning letters went to products that claimed to cure or prevent hangovers.
  • No endorsement of benefits. The proposal concerns legal status and safety, not whether NAC works for any particular use.
  • Drug NAC stays a drug. Prescription and hospital NAC are unaffected. That includes the approved acetylcysteine solution, which is inhaled to thin mucus or given by mouth as an acetaminophen overdose antidote, and the injectable antidote Acetadote. NAC supplements are not a substitute for emergency treatment of an overdose.

If you are choosing a product now, quality still varies. Our NAC supplements ranking compares products on dose and testing.

The bigger picture: drug preclusion

The proposal creates a list with room for more ingredients, but it does not name any others or set out a process for requesting that an ingredient be added. It only describes the two conditions the FDA would apply, each case through its own notice and comment rulemaking. The supplement industry welcomed the NAC proposal while pushing for more. In a November 16, 2026 statement, Steve Mister, president and CEO of the Council for Responsible Nutrition, a supplement trade group, said: "We welcome FDA's proposal to establish a regulatory pathway that would provide certainty for NAC." He added that the FDA "has opened the door for other ingredients to be considered, but it has not explained how manufacturers can walk through it."

That debate matters for consumers too. The drug exclusion clause protects people from drugs sold without proper review, and it protects the investment needed to develop new medicines. It can also exclude ingredients that have been sold as supplements for years without known safety problems. How the FDA balances those goals for future ingredients is still open.

How to comment

Anyone can comment on the proposal until 11:59 p.m. Eastern Time on January 19, 2027. Go to regulations.gov and search for docket number FDA-2025-N-2699. Comments submitted online are posted publicly as written, so do not include personal or medical information you would not want made public. If you need to submit confidential information, the FDA asks for a paper submission instead; the mailing instructions are in the Federal Register notice. The FDA specifically asks for:

  • Evidence that NAC was sold as a food or supplement before September 14, 1963
  • Comments on whether NAC supplement sales have affected, or could affect, NAC drug development
  • Comments on the proposed effective date and the cost estimates

Frequently asked questions

Is NAC legal to buy as a supplement?

You can buy NAC supplements in the US, and buying them is not illegal for consumers. The legal question is about how they are sold: the FDA still considers NAC excluded from the dietary supplement definition, but since 2022 it has said it does not intend to take action against NAC products that would otherwise be lawful supplements while it decides. In November 2026 it proposed a rule that would make NAC a lawful supplement ingredient. See our NAC supplements ranking.

What did the FDA propose about NAC in November 2026?

On November 17, 2026, the FDA proposed a rule finding that N-acetyl-L-cysteine is not excluded from the dietary supplement definition, and that adding it to a supplement is not a prohibited act. It would be listed in a new regulation, 21 CFR 190.1, as the first ingredient cleared this way.

Is the NAC rule final?

No. It is a proposed rule. The FDA is accepting public comments until January 19, 2027, and then must publish a final rule before NAC's legal status changes. The FDA proposes that a final rule would take effect as soon as it is published.

Why was NAC excluded from dietary supplements?

US law generally excludes an ingredient from the dietary supplement definition if it was approved as a drug before it was marketed as a supplement or food. NAC was approved as a drug in 1963, and the earliest supplement marketing the FDA found was in 1991.

Will NAC be banned?

Nothing in the proposal points that way. The FDA proposed making NAC a lawful supplement ingredient, and NAC supplements remain on sale under its temporary enforcement discretion policy while the rule is pending. The proposal is not final, so its details could still change after public comments.

Is NAC safe according to the FDA?

The FDA's systematic review of 41 high-confidence studies, at doses from 200 to 9,000 mg a day for up to 3 years, found a minimal level of concern. The side effects reported most often were stomach upset, nausea, vomiting and rash. NAC can still interact with some medicines, such as nitroglycerin, so check with a doctor or pharmacist if you take prescription drugs.

Does the FDA rule mean NAC works?

No. The proposal is about legal status and safety, not effectiveness. Like other supplements, NAC products could not claim to treat, cure or prevent any disease.

How can I comment on the FDA's NAC rule?

Go to regulations.gov and search for docket FDA-2025-N-2699. Comments are due by 11:59 p.m. Eastern Time on January 19, 2027, and online comments are posted publicly, so do not include personal or medical details you do not want shared.

Will other ingredients be added to the new list?

The proposed regulation reserves space for more ingredients, but the FDA has not named any others or set out a process for requesting additions. It says each exception would need its own rulemaking and would have to meet the same two conditions: adequate safeguards and no likely harm to drug development. The Council for Responsible Nutrition, a supplement trade group, has asked the FDA to clarify how other ingredients could qualify.

The bottom line

The FDA's November 2026 proposal would turn NAC from a technically excluded ingredient, sold under a temporary policy, into a lawful dietary supplement ingredient. It would be the first ingredient ever cleared through this part of the 1994 law. The agency's own safety review found a minimal level of concern at the doses people commonly take.

For now nothing changes on the shelf, and nothing about the proposal says NAC works for any particular purpose. If you take NAC, the same advice applies as before: choose a well-tested product, stay within studied doses, and check with your doctor or pharmacist if you take other medicines.

VS
Reviewed for accuracy by
Vladimir Salamakha

B.S. in Chemistry, University of South Florida · a formulation scientist with 15 years developing compliant, evidence-based products across nutritional supplements and personal care. More about the author →

A quick note This article summarizes a proposed federal rule and is general information, not legal or medical advice. Nothing here suggests that NAC or any supplement can diagnose, treat, cure, or prevent any disease. If you suspect an acetaminophen overdose, call 911 or Poison Control (1-800-222-1222) right away. If you take prescription medicines, are pregnant or breastfeeding, or have a chronic health condition, talk with your doctor or pharmacist before taking NAC.
Sources
US Food and Drug Administration. Rulemaking To Provide That N-acetyl-L-cysteine Is Not Excluded From the Dietary Supplement Definition. Proposed rule. Federal Register 91 FR 73717-73726, November 17, 2026. Docket No. FDA-2025-N-2699; RIN 0910-AI91. federalregister.gov/d/2026-23351. · US Food and Drug Administration. Policy Regarding N-acetyl-L-cysteine: Guidance for Industry. August 2022 (87 FR 47220). · US Food and Drug Administration. Safety Assessment for Ingested N-acetylcysteine Exposure: A Systematic Review. November 2026 (cited in the proposed rule as Reference 13). · Federal Food, Drug, and Cosmetic Act, sections 201(ff)(3)(B) and 301(ll), 21 U.S.C. 321(ff) and 331(ll). · Council for Responsible Nutrition. CRN Welcomes FDA's Proposed NAC Rule, Urges Broader Clarification of Drug Preclusion Framework. Press release, November 16, 2026. crnusa.org.